VeinTech Announces Opening of U.S. Headquarters in Providence, RI and Provides Company Updates
- Nikhilesh Bappoo
- Sep 30
- 4 min read
Perth, Australia-based expanding to U.S. with support of grant from the Rhode Island Life Science Hub
Flagship technology aims to transform IV insertion and improve patient outcomes
Recent clinical data validates the technology in 12 patients and demonstrates a strong potential use in cancer
Providence, RI and Perth, Australia — 22nd September 2025 – VeinTech, a MedTech innovator transforming vascular access, today announced the opening of its first U.S. office at CIC Providence. The launch was celebrated during Rhode Island Startup Week’s Health & Life Sciences Day on September 22, underscoring the state’s emergence as a hub for health innovation and economic growth.
Anchoring in Rhode Island’s Innovation Economy
VeinTech’s U.S. expansion is fuelled by a $750,000 Rhode Island Life Science Hub (RILSH) grant, which has accelerated the company’s entry into the U.S. market and enabled new collaborations with multiple local partners. From its roots at Perth Biodesign in Australia to support from NEMIC (New England Medical Innovation Center) in Providence, VeinTech’s journey reflects the power of international collaboration and Rhode Island’s growing life sciences ecosystem.
“VeinTech’s decision to establish a U.S. hub in Rhode Island is a powerful signal of the strength and momentum of our life sciences ecosystem,” said Mark Turco, MD, CEO of the Rhode Island Life Science Hub. “By tackling one of healthcare’s most widespread procedural challenges, VeinTech is showing how cutting-edge MedTech companies can drive both better outcomes for patients and new opportunities for economic growth. Their presence underscores why Rhode Island is becoming a destination for life sciences innovation.”
“With the support of RILSH, NEMIC, and our partners, we are thrilled to establish VeinTech’s U.S. headquarters in Providence,” said Dr. Nikhilesh Bappoo, CEO of VeinTech. “IV insertion is performed over a billion times each year, yet nearly half of those attempts fail on the first try. Our mission is to change that with VeinWise — giving every clinician the confidence to get it right the first time, and improving the experience for patients everywhere. Rhode Island offers the talent, resources, and partnerships we need to deliver on that vision.”
Driving Partnerships, Jobs, and Skills
Since receiving the RILSH grant, VeinTech has launched collaborations with local companies in product design, quality, regulatory, manufacturing and market access and is now seeking partnerships with clinical sites and nursing schools for upcoming validation studies.
Talent investment is central to VeinTech’s growth. The company recently announced the appointment of Michael Pereira, a veteran medical device industry operator who formerly served as COO of Beta Bionics and Ximedica, as Chief Operating Officer. VeinTech has also formed a cross-Atlantic scientific partnership in Galway, Ireland through the appointment of Scientific Advisory Board Chair, Associate Professor Peter Carr who joins the leadership team.
VeinTech will soon announce an incoming Chief Commercial Officer and is hiring additional staff and consultants in Rhode Island. The company is also partnering with the Rhode Island Life Sciences Workforce Development Partnership to create internships and training pathways for local students and early-career professionals.
In addition, VeinTech also welcomed Rhode Island medtech veteran and investor David Uffer to Perth as an Entrepreneur in Residence in June, strengthening transpacific innovation ties.
Transforming Healthcare & Creating Investor Opportunity
VeinTech is addressing one of healthcare’s most common yet deceptively difficult procedures—IV insertion. Its flagship product, VeinWise, is a portable imaging device that empowers any clinician to find the right vein, first time, every time. VeinTech’s flagship product empowers any healthcare worker—not just specialists—to confidently insert IVs with real-time vein visualization. The company is solving a deceptively simple but globally costly problem: failed IV insertions, which affect up to 40% of patients and cost billions in healthcare waste annually.
VeinTech recently presented its most recent clinical data at the Association for Vascular Access Conference in Orlando, demonstrating a strong potential use case in cancer centers and validating the technology in twelve patients. The company shared strong performance data indicating its ability to find “hidden veins” whilst enabling selection of higher-quality veins and sites that last longer, avoiding fragile hand veins or elbow creases prone to complications.
With this clinical momentum, VeinTech has now secured half of its upcoming $2.5M capital raise including $750K in non-dilutive funding from Rhode Island ahead of the round opening, to accelerate commercialization and U.S. market entry.
Media Contact
Sarah Sutton
Rhode Island Life Science Hub
(518) 932-3680
About VeinTech:
VeinTech is transforming one of healthcare’s most common yet deceptively difficult procedures—IV insertion. Our flagship product, VeinWise, is a portable imaging device that empowers any clinician to access the right vein, first time, every time. Backed by strong Australian and U.S. partnerships, over USD $4M raised, and recent USD $750K non-dilutive funding, VeinTech is poised for rapid commercial expansion, regulatory approval, and long-term market leadership.
About RILSH:
The Life Science Hub positions the state to deliver on a bold vision of transforming Rhode Island into a globally recognized life science innovation hub by coalescing existing stakeholders, activities, and investments while building new capabilities. Through an initial three-year, $45 million investment, the Hub will serve as the central and coordinating organization facilitating the development of medical advances and scientific breakthroughs by supporting companies that specialize in life sciences.
Media Contacts:
VeinTech:
Nikhilesh Bappoo Ph +61 406 659 568 E nbappoo@veintech.com.au
RILSH:
Sarah Sutton Ph +1 (518) 932-3680 E sarah@endurancepr.com